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CLINICAL EFFECTS OF ALLYLESTRENOL ON PATIENTS WITH 
BENIGN PROSTATIC HYPERPLASIA (BPH) EVALUATED 
WITH CRITERIA FOR TREATMENT EFFICACY IN BPH 
Kazumi NOGUCHI， Mitsumasa TAKEDA， Masahiko HOSAKA and Yoshinobu KUBOTA 
From the Department oJ Urology， Yokohama City University， School oJ Medicine 
One hundred and twenty-nine patients with benign prostatic hypertrophy (BPH) were registered 
and treated with allylestrenoI. Allylestrenol was administered at a dose of 50 mg/day given twice a 
day for 16 weeks. Out of 129 patients with a mean age of67.8 years old， 92 cases c∞omplet旬edthe study 
and 48 cases with moderate s町ympt旬omswere ob句jectivel片yevaluated w叩it出h
in BP目H"P戸ropos託edby The Japanese Urological Association in 1997. 
Prostate volume was significantly decreased from 32.7士11.9to 27.4:f: 11.2 ml (mean:fSD)， and 
maximum flow rate was significantly increased from 8.4:f3.4 to lO.8:f5.0 ml/sec. Residual urine 
volume was significantly decreased from 62.4土57.4to 37.0士38.7mI. IPSS was significantly 
decreased from 15.3士4.9to 9.9土4.0，and QOL index was significantly decreased from 4.4:f:0.8 to 
2.7:fL2. 
The efficacy of allylestrenol was shown by its effects on prostate volume (anatomy)， maximum 
urinary flow rate (function)， and symptom scores (symptom) at the end of 16 weeks oftreatment. The 
rates ofimprovement for symptoms， QOL， fu恥 tion，and anatomy are 68.7% (N=48)， 79.2% (N=48)， 
50.0% (N=48)， and 61.0% (N=41)， respectively. Overall efficacy (Good and Fair) was 70.9% 
(N=48). During this study， 5patients (3.9%) complained ofloss oflibido and 2 patients dropped out. 
In conclusion， alIylestrenol was demonstrated to be a quite effective and safe medical treatment for 
patients with symptomatic BPH based on the criteria for treatment efficacy in BPH. 
(Acta UroI. Jpn. 48: 269-273， 2002) 





























































65.1歳であり， 50歳代9例， 60歳代27例， 70歳代1
例， 80歳代 l例であった.治療前の前立腺重量は 20
gから 65gまで平均 32.7gであった.48症例中.前
治療を行っていた症例は6症例であり，いずれも植物











迫感J を除いてすべて有意に低下した (Table1). 


























Period of Treatment 
Objective parameters of patients with 
BPH during 16 weeks of treatment. 
P<O.OOI， P<O.OI: vs before therapy 
(OW) by paired t test (M:ISD). 
Table 1. Change of each subjective symptom 
score before and after the treatment 
with allylestrenol (N=48， M土SD)
治療前 治療後 P値
残尿感 2.18i:1.70 1.25i:0.95 <0.001 
2時間以内の排尿 2.54i: 1.51 1.79i:1.16 <0.001 
尿線の途絶 1.54i: 1.62 1. 04 i: 1.1 0.002 
尿意切迫感 0.54i:0.74 0.60i:0.93 0.56 
勢いの低下 3. 70i: 1. 32 2.3!:I: 1.24 <0.001 
開始時のいきみ 2.33土1.59 1.22土1.09 <0.001 
夜間排尿回数 2.39i: 1.33 1. 75士0.93 <0.001 
Total score 15.25:!:4.95 9.97:!:4.09 <0.001 
形態(体積)の各項目について判定した. IPSSにお

























Period of Treatment 
Subjective parameters of patients with 
BPH during 16 weeks of treatment 
P<O.OOI vs before therapy (0 W) by 










Table 2. Drug-related clinical adverse experi-
ence and abnormal laboratorγfind-
ings (N = 129) 
Parameter Incidence (%) 
Decreased libido 5 (3.9) 
Rash 2 (1.6) 
LDH incrcase 7 (5.4) 
Hb decrease 4 (3.1) 
BUN increase 3 (2.3) 
G PT increase 3 (2.3) 
Glycosuria 3 (2.3) 
TG increase 2 (1.6) 
、へIBCincrease 2 (1.6) 
ALP increase 1 (0.8) 
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Fig. 3. Clinical efficacy of allylestrenol was objectively evaluated accord-
ing to the “estimate criteria for efficacy of treatment on BPH" 
proposed by the japanese Urological Association in 1997. The 
rates of improvement for symptom (IPSS)， QOL (QOL index)， 
function (maximum ftow rate) ， and anatomy (prostate volume) 
were 68.7% (N=48)， 79.2% (N=48)， 50.0% (N=48)， and 61.0% 
(N=41)， respectively. Overall efficacy， the median of efficacy 
grades of 3 items: symptom， QOL and function， was 70.9% (N= 
48). Figures in each bar are numbers of patients. 



















な位置を占めるものと考えられる.土木ら 12)は， 1'1 
ブロッカー無効症例にアンチアンドロゲン剤を併用し
た際の有用性を報告している.すなわち塩酸タムスロ
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